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Abstract:  The ultimate goal in any biosensor development project is its use for actual 
sample  detection.  Recently,  there  has  been  an  interest  in  biosensors  with  aptamers  as  
bio-recognition elements, but reported examples all deal with standards, not human serum. 
In order to verify the differences of aptamer-based biosensor and antibody-based biosensor 
in  clinical  detection,  a  comparison  of  the  performance  of  aptamer-based  and  
antibody-based  quartz  crystal  microbalance  (QCM)  biosensors  for  the  detection  of 
immunoglobulin  E  (IgE)  in  human  serum  was  carried  out.  Aptamers  (or  antibodies) 
specific to IgE were immobilized on the gold surface of a quartz crystal. The frequency 
shifts  of  the  QCM  were  measured.  The  linear  range  with  the  antibody  (10–240  μg/L) 
compared  to  that  of  the  aptamer  (2.5–200  μg/L),  but  a  lower  detection limit could  be 
observed in the aptamer-based biosensor. The reproducibility of the two biosensors was 
comparable. The aptamers were equivalent or superior to antibodies in terms of specificity 
and  sensitivity.  In  addition,  the  aptamer  receptors  could  tolerate  repeated  affine  layer 
regeneration  after  ligand  binding  and  recycling  of  the  biosensor  with  little  loss  of 
sensitivity. When stored for three weeks, the frequency shifts of the aptamer-coated crystals 
were all greater than 90% of those on the response at the first day. 
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1. Introduction  
Systematic evolution of ligands by exponential enrichment (SELEX) is an iterative selection 
procedure used to identify oligonucleotides with desired properties. The SELEX-derived aptamers 
generally have a high degree of similarity to antigen–antibody binding in both their specificity and 
affinity.  Aptamers  are  synthetic,  single-stranded  DNA  or  RNA  molecules  that  fold  up  into  
unique 3-D structures, which allows them to specifically bind to other target molecules. Since 
their discovery about 20 years ago [1,2], aptamers have exhibited high affinity to their targets with 
Kd values in the low nanomolar to picomolar range. Closely related isoforms, and even different 
conformational states of the same target molecule can be discriminated by using the aptamers with 
high  specificity  [3,4].  Due  to  these  characteristics,  aptamers  have  been  successfully  used  in 
different  areas  of  biotechnology  such  as  purification  processes  [5],  target  validation  [6],  drug 
discovery [7], diagnostics [8], and therapy [9,10]. 
Recently, the stability and convenience of DNA aptamers have been exploited in diagnostic 
applications  including  biosensors  [11,12]  and  flow-cytometry  assays  [13].  In  comparison  to 
antibodies, aptamer receptors have a number of advantages. The main advantage is the avoidance 
of  the  use  of  animals  for  their  production.  Moreover,  the  aptamer  selection  process  can  be 
manipulated  to  obtain  aptamers  that  bind  to  a  specific  region  of  the  target  and  with  specific 
binding properties under different binding conditions. After selection, aptamers are produced by 
chemical synthesis and can be purified to a very high degree thus eliminating the batch-to-batch 
variation found when using antibodies. At the same time, modifications in the aptamer can be 
introduced to enhance the stability, affinity and specificity of the molecules. Finally, while many 
antibodies  are  temperature-sensitive  and  can  denature  upon  contact  with  surfaces,  leading  to 
limited shelf lives and possible compromise of assay integrity, aptamers are stable to long-term 
storage  [14-17].  Aptamers  usually  retain  their  binding  and  inhibitory  behavior,  even  after 
immobilization on carrier material [18]. Aptamers can be transported at ambient temperature, and 
undergo reversible denaturation. Consequently, aptamers offer a useful alternative to antibodies as 
sensing molecules, especially in the development of biosensors for chemicals [19-21]. 
The key issue in the development of aptamer-based sensors is to convert target recognition into 
a measurable signal. QCM crystal transducers are known to be highly precise, stable oscillators 
and are capable of detecting subnanogram mass changes [22]. Several authors have reported direct 
comparisons  between  aptamers  and  antibodies  specific  for  the  same  target  when  used  as  
bio-recognition  element  in  biosensors.  An  anti-IgE  DNA  aptamer  was  compared  with  the 
monoclonal  antibody  for  the  same  target  (IgE)  in  a  quartz  crystal  biosensor  [20].  The  two 
receptors both achieved a detection limit of 0.5 nM for IgE, but the aptamer-based one showed  
a  10-fold  extended  linear  range.  The  same  kind  of  comparison  has  been  performed  on  a 
piezoelectric  biosensor  using  an  RNA  aptamer  specific  for  HIV-1  Tat  protein  and  the 
corresponding monoclonal antibody [21]. In this case an extended linear range was obtained with Sensors 2010, 10                                       
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the  antibody-based  biosensor,  but  the  aptamer-based  sensor  showed  better  sensitivity.  The 
reproducibility of the two biosensors was comparable and a good specificity was observed with 
both the receptors.  
We have set up a QCM immunosensor platform and successfully quantified human chorionic 
gonadotropin [23] and urinary protein [24]. The ultimate goal in biosensor development is to be 
able to use for clinical detection. Recently, there has been an interest in biosensors with aptamers 
as bio-recognition elements, but the reports all deal with standards. To the best of our knowledge, 
there  are  no  reports  of  biosensors  for  detection  of  human  serum.  In  a  previous  study,  we 
constructed  an  aptamer  biosensor  and  used  it  for  serum  detection  [25]. In  order  to  verify  the 
differences between aptamer-based antibody-based biosensors in clinical detection, a comparison 
between the two methods was done and the main analytical parameters of the two biosensors, such 
as sensitivity, selectivity and reproducibility, have been studied. 
2. Results and Discussion  
2.1. Aptamer-Based Biosensor vs. Antibody-Based Biosensor: Comparison of Sensitivity 
We compared the aptamer-based biosensor with the antibody-based biosensor with respect to 
achieved sensitivity and selectivity. The aptamer and antibody-coated crystals were incubated in 
IgE solutions in a range from 2.5–250 μg/L, both aptamer and antibody-based crystals showed 
typical binding capacity saturation. Theaptamer-based biosensor displayed signal saturation at the 
concentration  of  200  μg/L  IgE.  The  antibody-based  biosensor  performed  similarly,  but  not 
exhibiting saturation below a concentration of 240 μg/L IgE. Although aptamers were likely to be 
immobilized in a denser arrangement than antibodies due to their smaller size, signal saturation 
did not shift to higher concentrations. This effect may be caused by steric hindrance between 
bound analyte molecules. The antibody-based biosensor generated significantly lower detection 
signals (ΔF), possibly caused by partial denaturation of the immobilized antibodies on the surface 
of  crystals,  leading  to  a  decreasing  number  of  correctly  folded  antibodies  being  available  for 
specific analyte recognition. 
Concerning the limit of detection, aptamers were proved to be superior compared to antibodies. 
The  limit  of  detection  (S/N,  >3)  was  measured  on  20  consecutive  negative  controls.  
The  antibody-based  biosensor  was  able  to  specifically  detect  IgE  at  a minimum concentration  
of  10  μg/L.  In  addition,  specific  analyte  recognition  by  the  aptamer-based  biosensor  could be 
observed  down  to  a  concentration  of  2.5  μg/L  in  the  binding  assay.  This  result  most  likely 
reflected the dense and highly ordered nature of the aptamer receptor layer. The reaction time to 
reach equilibrium for both biosensors was 15 min. In a previous approach, anti-IgE antibodies and 
aptamers  were  compared  as  receptor molecules using a quartz crystal microbalance biosensor. 
Both receptor types detected IgE specifically at a minimum concentration of 95  μg/L [20]. The 
different sensitivity in that work could be partly attributed to the bigger gold surface (a diameter  
of 8 mm) of the PZ crystal they used. This usually results in a lower sensitivity. The aptamers they 
used  were  modified  and  had  a  longer  sequence,  that  maybe  another  reason  for  the  different Sensors 2010, 10                                       
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sensitivity.  This  sensitivity  is  comparable  or  better  than  that  of  other  reported  aptamer-based 
analytical methods for IgE detection (Table 1). 
Table 1. Summary of the IgE determination limit obtained by various methods. 
Method [reference]  Detection limit 
QCM 
CE [26] 
ELISA [27]
 a 
Molecular Light Switch Complex [28] 
Fluorescence Anisotropy [29] 
Electrochemical Sensor [30] 
50 pM 
46 pM 
45 pM 
100 pM 
350 pM 
158 pM 
aELISA  method  used  antibody  as  bio-recognition  element; 
other methods used aptamer as bio-recognition element. 
2.2. Comparison of Imprecision  
Imprecision data for the determination of IgE (2.5–200 μg/L) by the aptamer or antibody-based 
biosensor  was  compared  intraassay  and  interassay.  For  every  concentration,  tests  were  
repeated 20 times in one day for intraassay and repeated on 20 consecutive days in the same manner 
(mean of three duplicates per day) for interassay reproducibility. The mean intraassay and interassay 
CV of aptamer-based biosensor were 4.14% and 5.95%, respectively. Similarly, the intraassay and 
interassay  CV of the antibody-based biosensor were 4.18% and 6.13%. Variable surface  coverage 
between manually produced sensing elements might account for this precision difference. Large-scale, 
automated fabrication of aptamer biosensors would likely yield much more uniform surface coverage 
and a correspondingly lower CV. 
2.3. Accuracy of the QCM Biosensor  
We further tried IgE detection in human serum containing a variety of proteins, including different 
types of immunoglobulins. IgE concentrations in clinical human serum samples were simultaneously 
measured  by  the  QCM  biosensor  and  the  chemoluminescence  method.  Mean  values  by  the  
aptamer-based QCM biosensor, antibody-based QCM biosensor and chemoluminescence in 50 clinical 
human  serum  samples  were  64.0,  62.6  and  64.9  μg/L,  respectively,  with  ranges  of  3–215,  5–234  
and 5–208 μg/L. To investigate the correlation of the QCM biosensor with the chemoluminescence 
method, the Bland-Altman difference plot analysis for the clinical sample detection results was done 
(Figure 1). A Bland-Altman difference plot analysis for the aptamer-based QCM biosensor showed a 
mean  difference  (QCM  minus  chemoluminescence)  of  2.12  μg/L,  and  the  limits  of  agreement  
(d – 1.96S to d + 1.96S, –11.12 to 15.56 μg/L) were sufficiently narrow, suggesting good consistency 
and clinical comparability between these two methods. However, the antibody-based QCM biosensor 
had a wider range of agreement limit. The result showed that the IgE concentration in clinical serum 
samples was positively related to the frequency shift of the QCM biosensor. The consistency between 
QCM aptamer biosensor and chemiluminescence method is good, indicating that it is possible to detect Sensors 2010, 10                                       
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IgE in clinical serum samples using the QCM aptamer biosensor and the  analytical sensitivity and 
accuracy of the QCM biosensor is sufficient for the detection of IgE from serum samples. 
Figure 1. Bland-Altman difference plot for IgE detection results by QCM biosensor and 
chemoluminesence method. On the horizontal axis, plot the mean of results by the two 
studied  methods.  (A)  Bland-Altman  difference  plot  comparing  IgE  detection  results 
obtained  with  aptamer-based  QCM  biosensor  against  Chemoluminesence  (Beckman).  
(B)  Bland-Altman  difference  plot  comparing  IgE  detection  results  obtained  with  
antibody-based QCM biosensor against Chemoluminesence. The solid line represents the 
mean difference in quantitative measurement of IgE between the two methods, and the 
dashed lines are mean ± 1.96 SD. 
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2.4. Comparison of Selectivity  
One of the greatest challenges a protein biosensor faces is nonspecific binding, which results in high 
background signals and therefore decreasing assay sensitivity. In this respect, a comparison between 
the signal intensities of specific IgE recognition with nonspecific protein binding again emphasized the 
superiority of aptamers. To test the specificity of the aptamer, proteins with different molecular weight 
and isoelectric point were used. The interfering proteins that were tested included HSA, lysozyme, IgG, 
and  IgM.  These  proteins  were  chosen  to  cover  the  range  of  possible  interfering  molecules  in  the 
detection  of  IgE.  HSA  has  a  much  smaller  molecular  weight  (MW  66,000)  with  respect  to  IgE  
(MW 190,000), whereas IgG is structurally similar to IgE and thus can serve as a good test protein for 
the  aptamer  binding  specificity.  The  concentration  of  the  interfering  proteins  was  chosen  to  
be 500 mg/L; it was a very high concentration compared with the tested IgE. The relative responses of 
the interferences, as seen in Figure 2, were insignificant in comparison to the specific binding response 
with IgE. The testing concentration of IgE was chosen as 100 μg/L since at this concentration the 
specific signal for IgE resulted in a lower CV. These experiments demonstrated the high specificity of 
the sensor with the immobilized aptamers, as a significant frequency shifts were obtained only when 
testing the specific protein. The cross-reactivity of the aptamers was thus seen to be less than 5% for all 
the interferences considered. The relatively low cross-reactivity of aptamer toward HSA, IgG and IgM 
considered here was very encouraging, considering the high percentage of these proteins in serum. Sensors 2010, 10                                       
 
 
5864 
Lysozyme is a particularly good control in this experiment, because it has a very high basic charge  
(pI = 9.1) and is known to bind nonspecifically to nucleic acids. The results demonstrated that the 
contribution to the binding of the mere electrostatic interaction was reduced when considering the 
selected  aptamer  with  its  secondary  structure.  Therefore,  nonspecific  binding  did  not  affect  the 
analytical data. In contrast, binding assays carried out on antibody-coated crystals resulted in higher 
signal  background  and  therefore  lower  selectivity.  It  could  be  clearly  demonstrated  that  aptamers 
showed higher selectivity compared to antibodies, indicating strikingly higher specificities. 
Figure 2. Comparison of the detection specificity between aptamer-based biosensor and 
antibody-based  biosensor.  The  HSA,  IgG  and  IgM  were  tested  at  a  concentration  
of 500 mg/L and diluted in the same buffer (10 μM Tris-HCl buffer, pH 7.9) (interaction 
time:  15  min).  The  lysozyme  was  tested  at  a  concentration  of  1  mg/L.  The  testing 
concentration of IgE was 100 μg/L. 
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2.5. Comparison of Regeneration and Long-Time Stability  
The regeneration of binding surfaces is important for reusable biosensors but it often difficult to 
achieve.  We  tried  to  regenerate  the  biosensor  surface  after  binding  of  IgE  by  rinsing  the  
antibody-coated crystals with 0.2 mmol/L glycine/HCl (pH 2.8), or 1.2 mmol/L NaOH, the common 
regents for dissociating antibody-antigen complexes. This resulted in a complete release of the analyte. 
However,  all  subsequent  injection  of  IgE  only  led  to  reduced  frequency  changes.  Apparently,  the 
receptor layer was either irreversibly damaged or the antibodies were unfolded. The refolding of the 
antibodies was too inefficient to be effective before subsequent injection of the analyte. Although the 
antibody-based  biosensor  could  be  reusable,  a  loss  of  activity  of  the  immobilized  antibody  
was inevitable. 
Unlike the antibody-based biosensor, the aptamer-based biosensor could be denatured and reused 
many times on the same chip, without loss of function. Binding of IgE to the aptamers was an almost 
completely  reversible  procedure.  As  shown  in  Figure  3,  using  30  mmol/L  EDTA  as  regeneration 
reagent led to dissociation of the analyte. The aptamer layer being completely reconstituted simply by 
returning to original buffer conditions (PBS). The crystals could be used continuously for 10 times, and 
the relative frequency shifts obtained were all more than 80% of the response obtained at the first Sensors 2010, 10                                       
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cycle. The regeneration procedure also had been proved to be simplistic with just EDTA. This is 
because IgE aptamers need bivalent metal ions to assemble into their three-dimensional structure and 
unfold in the presence of EDTA. They refold very rapidly when EDTA is withdrawn and replaced by  
Mg
2+-containing buffer [20].  
Figure  3.  Comparison  of  the  regeneration  between  aptamer-based  biosensor  and  
antibody-based biosensor by EDTA. IgE (100 μg/L) was applied to the gold surface for 
detection. The regeneration reagent was 30 mmol/L EDTA solution. The relative frequency 
shift  (%)  was  the  frequency  shift  measured  relative  to  the  response  for  the  first 
measurement. The cycles of x-axis mean the number of the regeneration test. 
 
 
Aptamer or antibody-coated crystals were covered with 0.02% sodium azide solution in PBS and 
stored at 4 ° C for long-time stability test. We made three different crystals for measurement per day 
continuously  for  35  days.  At  the  end  of  the  third  week,  the  loss  of  adsorbed  surface  mass  was 
calculated  to  be  only  10%,  indicating  loss  of  probes  was  negligible  over  this  time  period  for  
aptamer-coated crystals. For antibody-coated crystals, the stability was almost fully maintained at the 
first  two  days  and  then  started  to  decline.  After  one  week,  the  relative  frequency  shifts  of  
antibody-coated crystals were about 40% compared with its initial response. This is because that the 
antibodies are sensitive to temperature and undergo irreversible denaturation. The antibodies also have 
a limited shelf life. The reusability and long-time stability of the aptamer-based biosensor showed that 
the cost of detection could be reduced by this method. 
3. Experimental Section  
3.1. Reagents 
Avidin,  3,3’-dithiodipropionic  acid  di(N-succinimidyl  ester)  (DSP),  N,N-dimethylacetamide 
(DMA), staphylococcal protein A (SPA), and lysozyme were purchased from Sigma (St. Louis, MO, 
USA). Bovine serum albumins (BSA) and human serum albumins (HSA) were purchased from Roche 
(Indianapolis, IN, USA). IgE, IgG and IgM were purchased from US Biological Company (Boston, 
Massachusetts,  USA).  All  the  other  reagents  were  purchased  from  Sigma  (St.  Louis,  MO,  USA). Sensors 2010, 10                                       
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Monoclonal  anti-human  IgE  antibody  was  purchased  from  Beckman  (St.  Louis,  MO,  USA).  The 
composition of the buffers used for the experiments is reported below: 
Immobilization buffer: 10 μM Tris-HCl buffer, 0.2 M NaCl, pH 7.9. 
Reaction buffer: 8.1 mM Na2HPO4, 1.1 mM KH2PO4, 1 mM MgCl2, 2.7 mM KCl, and 138 mM 
NaCl, the pH was adjusted to 7.4, which was based on the reported SELEX conditions [29]. 
The base sequence for the anti-IgE aptamer (D17.4) has been found to be 5’-GGGGCACGTTTAT-
CCGTCCCTCCTAGTGGCGTGCCCC-3’,  as  noted  from  the  initial  work  of  Wiegand  and  
co-workers [31]. The aptamer with the 5’-modified with biotin was custom designed and purchased 
from Shanghai Bioengineering Company (Shanghai, China). 
3.2. Apparatus 
The 10 MHz AT cut quartz crystal (13 mm ×  13 mm) with gold evaporated on both sides was 
obtained from 26th Research Institute, Chinese Electronic Scientific and Technical Group Company 
(Chongqing,  China).  The  2  ×   5  model  micro-array  sensor  was  made  by  China  Jialing  Group 
(Chongqing,  China).  The  frequency  variations  were  continuously  recorded  using  a  frequency  data 
acquisition card (Model PCL-836, Yanhua Co., Taiwan, China): the data (the resonance frequency) 
was  displayed  on  the  display  screen  and  could  be  read  directly  by  a  computer  connected  to  the  
PCL-836 interface. The frequency shifts reported were the difference between two stable frequency 
values (ﾱ1 Hz). The cell was used in static conditions. Temperature was controlled (≤1 °C) by an air 
thermostat. The measuring apparatus consisted of the crystals fixed inside the sensor, only one side of 
which was exposed to the solutions. All detection wells were designed with the same structure, and 
each of them was driven by an independent logic circuit so that they worked independently, without 
mutual interference. The electrode surface was soaked and rinsed for 10 min in cleaning solution (30% 
H2O2: 98% H2SO4 = 1:3) and then thoroughly washed with tri-distilled water and dried with pure 
nitrogen gas. 
3.3. Immobilization of Aptamer  
Immobilization of aptamers on gold-coated quartz crystals was performed as follows: the prepared 
gold  surfaces  were  activated  by  injection  with  10  μL  of  4  mg/mL  DSP  in  water-free  DMA,  and 
incubated at room temperature for 15 min. The gold surfaces were then washed three times with PBS, 
followed by the immediate injection with 10 μL of 2 mg/mL avidin in PBS, and incubated at 4 ° C 
overnight. The 5’-biotin-labeled aptamer solution at a concentration of 2 μmol/mL was heated to 95 °C 
for  3  min  and  chilled  on  ice  to  place  the  aptamer  in  its  favorable  thermodynamic  conformation. 
Subsequently, 10 μL of aptamer solution was added onto the gold surface of the crystals, and incubated 
at room temperature for 1 h. Unbounded aptamers were removed by rinsing with PBS buffer three 
times. To block unreacted surface groups, 10 μL of 0.025% BSA solution was applied; the slides were 
then incubated at room temperature for 1 h and rinsed by PBS buffer three times. Aptamer-coated 
crystals were either used immediately or covered with 0.1% sodium azide solution in PBS and stored  
at 4 ° C. Sensors 2010, 10                                       
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3.4. Immobilization of Antibody 
First, 5 mL of 1 mg/mL SPA solution in PBS was injected on the gold surface of the crystals  
for 20 min, following by a through rinse with PBS buffer to remove the unreacted SPA. Then 10 μL  
of 5 mg/mL anti-IgE antibody was added on the gold surface of the crystals after the activation with 
SPA. After 20 min the antibody was washed off and the remaining activated sites of the layer were 
saturated with BSA as described in Section 3.3. 
3.5. Detection Procedures  
Ten  prepared  crystals  were  placed  into  the  detection  wells  with  the  side  coated  with  aptamer  
(or antibody) facing up to construct the 2 ×  5 model array. The system temperature was adjusted  
to 37 ° C. Then, 90 μL of reaction buffer was added to each cell of the sensor. The resonance frequency 
(F0)  was  monitored  until  a  steady  baseline  was  obtained.  Then  10  µL  IgE  standards  of  different 
concentrations  (2.5–250  μg/L)  were  added  into  the  wells  respectively.  PBS  buffer  was  added  to 
chamber 10 as a negative control. When the resonance frequency reach a stable value, that means the 
reaction between the aptamer (or antibody) and the IgE came to an end. Then, another steady state 
resonant  frequency was taken as F1. The frequency shifts (ΔF = F1 – F0) induced by aptamer-IgE  
(or antibody-IgE) were the difference between the final  value (F1) and the value displayed before 
reaction (F0). The equilibrium time for reaction was also recorded. The average value was taken by 
repeating the experiment 3 times. The dose-curve was drawn according to the relationship between 
frequency shifts and IgE concentrations. Human IgG, IgM, and HSA (Sigma) were used as nonspecific 
binding controls. All proteins were dissolved in a PBS buffer at a concentration of 500 mg/mL, which 
served as a stock solution. 
3.6. Regeneration Procedures 
The regeneration of the crystals used is an important factor to be considered in the development of a 
practical biosensor. The regeneration solution, 0.2 mmol/L glycine/HCl (pH 2.8), 1.2 mmol/L NaOH, 
and 30 mmol/L EDTA, were applied on the electrodes for two minutes to denature the aptamer or 
antibody and remove the IgE from it after each measurement. The obtained surfaces were then rinsed 
with PBS buffer three times. After washing with tri-distilled water the frequency reached a stable value 
(± 1 Hz) with buffer, aptamer or antibody once again responded to the IgE and a new detection step 
could be performed. 
3.7. Materials Methodology Comparison 
First, we generated the calibration curves by plotting ΔF against various IgE concentrations, and the 
linearity was determined by serially diluting the stock IgE solutions. After the analysis procedures, the 
operational  characteristics,  including  imprecision,  accuracy,  specificity,  analytical  sensitivity,  and 
detection limit, were evaluated. Then, the serum samples were quantified individually with the QCM 
biosensor  and  chemiluminescence  (Access  Immunoassay  System,  Beckman).  All  participants  gave 
signed  informed  consent  and  the  study  was  approved  by  the  Ethics  Boards  of  the  Third  Military Sensors 2010, 10                                       
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Medical  University.  Bland-Altman  analyses  were  performed  to  evaluate  the  residuals  plots  of  the 
proposed methods and reference method. 
3.8. Statistical Treatment 
The results  are expressed as mean (± SD). SPSS  10.0 software was used for the t-test, and the  
Bland-Altman analyses were performed with GraphPad, version 5.0. 
4. Conclusions  
Antibodies and aptamers can bind to their targets with high affinity and specificity, aptamers offer 
distinct  advantages  over  antibodies  that  make  them  very  promising  in  analytical  and  diagnostic 
applications.  These  advantages  include  the  easily  regenerating  the  function  of  the  immobilized 
aptamers and the possibility of using different detection methods due to easy labeling [32,33]. Due to 
their  high  binding  affinity,  simple  synthesis,  easy  storage,  and  wide  applicability,  aptamers  are 
emerging as  a new class of molecules that rival commonly used antibodies in protein recognition  
and detection. 
Here we assessed a DNA-aptamer as an affinity ligand, and it compared favorably with its antibody 
counterpart. Compared to antibodies (10 ng/mL), aptamer-based analyte recognition was at least as 
sensitive.  Aptamers  could  detect  their  analytes  (IgE)  at  a  minimum  concentration  of  2.5  ng/mL. 
Regarding  specificity,  aptamers  were  even  superior  to  antibodies,  which  exhibited  higher  signal 
backgrounds  due to  a higher degree of nonspecific protein binding. Moreover, for clinical sample 
detection, the consistency between QCM aptamer biosensor and chemiluminescence method is good. 
Another advantage over antibodies can be seen in the higher stability of aptamers, as aptamers are very 
stable and they can recover their native active conformation after denaturation. The results suggested 
that the aptamer-based biosensor was sensitive, specific, and easy-operating method. These results 
raise  the  prospect  that  aptamers  could  be  adapted  to  function  as  reusable,  long-time  biosensors  
in arrays.  
Recently, there has been an interest in biosensors with aptamers as the bio-recognition element. In 
most cases, only limited quantities of IgE from standards are available by QCM biosensor. To achieve 
the object of detecting IgE in clinical serum samples, we combined QCM and aptamer together. QCM 
has high sensitivity and aptamer has high selectivity. Combining the two elements together, sensitivity 
was greatly enhanced, and detection can be performed directly on clinical serum samples. Our results 
showed  that  this  system  can  detect  about  2.5  ng/mL IgE,  making it a  feasible assay for practical 
applications. In conclusion, this aptamer-based QCM biosensor can directly detect IgE from clinical 
serum samples with high sensitivity and selectivity. It may be a rapid, efficient and simple approach for 
detection of IgE in clinical specimens. Given that QCM immunosensor analyses are fairly rapid and 
relatively easy to operate, this approach lends itself particularly well to the rapid development of an 
analytical method in clinical laboratories. Sensors 2010, 10                                       
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